跳至主要内容
临床试验/CTIS2022-501106-35-00
CTIS2022-501106-35-00进行中(未招募)1 期

I8F-MC-GPHJ: A Phase 3b, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 mg in Adults Who Have Obesity or Overweight with Weight-Related Comorbidities - 17203

Eli Lilly & Co.0 个研究点目标入组 700 人开始时间: 2022年10月11日最近更新:

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
700

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 65+(—)
性别
All

入选标准

  • Have obesity, Have overweight with at least one: Obstructive sleep apnea, have high blood pressure, have high cholesterol, have heart disease

排除标准

  • Have type 1 or type 2 diabetes, Have a self-reported change in body weight over 5 kg within 3 months before screening, Have a planned or prior surgery for obesity, Have severe” kidney impairment, Have long-term or short- term inflammation of the pancreas

研究者

相似试验